Graphene Quantum Dots for Lysosomal Storage Disorder Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for lysosomal storage disorders (LSDs) are limited, as they often target specific enzyme deficiencies, making it challenging to develop a therapeutic agent effective across various LSDs.
Innovation Solution
A pharmaceutical composition incorporating graphene quantum dots as an active ingredient, which inhibits the accumulation of substrates in lysosomes or decomposes previously accumulated substrates by binding to unmetabolized substrates using a negative charge generated on its surface.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional enzyme replacement therapies are used for specific lysosomal storage disorders, then treatment effectiveness for that specific disease is improved, but applicability to other LSDs deteriorates
Solution Approach 1:
The patent applies universality by developing a single therapeutic agent (graphene quantum dots) that can treat multiple different lysosomal storage disorders through a common mechanism (binding to unmetabolized substrates), replacing the need for multiple disease-specific enzyme replacement therapies
Solution Approach 2:
The patent uses graphene quantum dots as an intermediary substance that binds to unmetabolized substrates in lysosomes, facilitating their removal or decomposition without requiring the specific deficient enzyme, thus serving as a universal mediator for various LSDs
2Measurement precision
If disease-specific enzyme replacement therapies are developed, then therapeutic precision for that disease is improved, but development complexity for multiple diseases increases
Solution Approach 1:
The patent reduces development complexity by creating a single universal therapeutic agent (graphene quantum dots) that addresses multiple LSDs simultaneously, eliminating the need to develop and maintain separate enzyme replacement therapies for each disease
3Stability of the object's composition
If substrate accumulation is allowed to proceed, then natural disease progression occurs, but cellular function deteriorates
Solution Approach 1:
The patent converts the harmful accumulated substrates into beneficial outcomes by using graphene quantum dots to bind to these substrates, preventing further accumulation and enabling their decomposition or removal, thus transforming the pathological substrate buildup into a treatable condition
Solution Approach 2:
The patent introduces graphene quantum dots as an intermediary that binds to unmetabolized substrates in lysosomes, preventing their harmful accumulation and facilitating their decomposition or removal, thereby restoring cellular function without requiring the deficient enzyme
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The composition effectively prevents or treats LSDs by inhibiting substrate accumulation and decomposing existing substrates, thereby alleviating symptoms and improving cellular function.
Implementation Method 1
graphene quantum dots may inhibit accumulation of substrates in lysosomes or decompose previously accumulated substrates by binding to unmetabolized substrates
Implementation Method 2
graphene quantum dots may inhibit accumulation of substrates in lysosomes or decompose previously accumulated substrates by binding to unmetabolized substrates
Data Source
AI summary
Provided is a method for prevention or treatment of a lysosomal storage disorder, and more particularly, to a method that may exhibit excellent efficacy against various lysosomal storage disorders including Niemann-Pick disease by including graphene quantum dots.